HELP FOR TODAY. HOPE FOR TOMORROW
HDSA Mission - The Society is a National, voluntary health organization dedicated to improving the lives of people with Huntington’s Disease and their families. To promote and support research and medical efforts to eradicate Huntington’s Disease. To assist people and families affected by Huntington’s Disease to cope with the problems presented by the disease. To educate the public and health professionals about Huntington’s disease.

www.hdsa.org

The HDLighthouse mission is to present and explain the latest research findings so that HD families can become proactive in their care, have hope for the future, and make good decisions in the present.

www.hdlighthouse.org

The Huntington Study Group (HSG) is a non-profit group of clinical investigators from medical centers in the United States, Canada, Europe and Australia, experienced in the care of patients and families affected by Huntington disease and dedicated to clinical research of this hereditary disorder. The HSG focuses on the conception, conduct and communication of clinical research, including treatment trials and observational studies aimed at relieving the burden and slowing the progression of Huntington disease. Please see Clinical Trials in Progress for the current HSG trials.

www.huntington-study-group.org

There is hope on the horizon for people with Huntington’s Disease. There are many Clinical Studies underway, and a number of potential therapies may move into Clinical Trial phases in the very near future. Volunteers are needed for ongoing trials and many more will be needed for future trials.
HDTrials.org has been created to enable clinical trial participation, the HDTrials.org web site will provide quick notification to Huntington families of opportunities for participation in clinical trials and studies through a confidential email list.

www.hdtrials.org

NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on the Nasdaq OMX Copenhagen A/S.

The core business of the company covers the development of novel pharmaceutical agents, based on a broad and well-established drug discovery platform focusing on ion channels and central nervous system (CNS) disorders.

A substantial share of the activities is partner financed through strategic alliances with Eli Lilly and Company, Janssen Pharmaceutica and GlaxoSmithKline (GSK), and a license collaboration with Abbott.


The drug pipeline comprises eight clinical (Phase I-III) development programmes: Huntexil™ (pridopidine) for Huntington’s disease (Phase III), tesofensine for obesity (Phase III ready), ABT-894 for ADHD (Phase II) in partnership with Abbott, ACR343 for schizophrenia (Phase II ready), ACR325 to treat dyskinesias in Parkinson’s disease (Phase Ib), ABT-560 for the treatment of cognitive dysfunctions (Phase I) in collaboration with Abbott, NSD-788 for anxiety (Phase I) and NSD-721 for social anxiety disorder (Phase I) in partnership with GSK.


In addition, NeuroSearch has a broad portfolio of preclinical drug candidates and holds equity interests in several biotech companies.

Lundbeck A/S is an international pharmaceutical company with more than 50 years of experience in research, development, production, marketing and sale of pharmaceuticals for the treatment of diseases of the central nervous system.

Xenazine®* (tetrabenazine) is a product of Lundbeck. Xenazine® is the first and only FDA-approved therapy for the treatment of chorea associated with Huntington’s disease. Xenazine® was approved by the FDA in August 2008 and was launched by Lundbeck Inc. in November 2008. Xenazine® was granted Orphan Drug status from the FDA, providing seven years of market exclusivity.